Quince Therapeutics (QNCX) CEO moves 739,885 common shares to Thye Trust

Rhea-AI Filing Summary

Quince Therapeutics, Inc. insider Dirk Thye, who serves as director and as CEO and CMO, reported a transfer of common shares dated 12/10/2025.

The reported transaction with code G involved 739,885 common shares at a stated price of $0, moving from direct to indirect beneficial ownership through the Thye Trust. After this transaction, Thye held 255,000 common shares directly and 739,885 common shares indirectly via the Thye Trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thye Dirk

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CMO

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/10/2025		G		739,885	D	$0	255,000	D
Common Shares	12/10/2025		G		739,885	A	$0	739,885	I	Thye Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Brendan Hannah as attorney-in-fact for Dirk Thye	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Quince Therapeutics (QNCX) report?

Quince Therapeutics reported that insider Dirk Thye739,885 common shares were reclassified from direct to indirect ownership through the Thye Trust at a stated price of $0.

How many Quince Therapeutics (QNCX) shares were transferred by Dirk Thye?

The transaction shows 739,885 common shares of Quince Therapeutics involved in a code G transaction on 12/10/2025 at a price of $0.

What is Dirk Thye’s role at Quince Therapeutics (QNCX)?

Dirk Thye is listed as a director and an officer of Quince Therapeutics, serving as the company’s CEO and CMO.

How many Quince Therapeutics shares does Dirk Thye hold after the transaction?

Following the reported transaction, Dirk Thye held 255,000 common shares directly and 739,885 common shares indirectly through the Thye Trust.

When did the Quince Therapeutics (QNCX) insider transaction take place?

The earliest transaction date reported for the insider activity is 12/10/2025.

How is Dirk Thye’s indirect ownership in Quince Therapeutics structured?

The filing shows 739,885 common shares of Quince Therapeutics held indirectly with the nature of beneficial ownership described as the Thye Trust.